Regina Barragán-Carrillo, MD, on Breast Cancer Screening in the Transgender Population

2022 ASCO Quality Care Symposium


Regina Barragán-Carrillo, MD, of Mexico’s National Institute of Medical Sciences and Nutrition Salvador Zubirán, discusses her findings showing that currently, physicians have limited knowledge about breast cancer screening in transgender patients. Were this topic addressed with widespread information, it could possibly reduce the health-care inequalities faced by this diverse group of patients (Abstract 71).


Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Transgender patients experience intersected forms of marginalization, and also suffer significant healthcare disparities. It is known that gender minorities present a disproportionate cancer burden, and are also diagnosed at later stages. Specifically, in the case of breast cancer, over 40% of transgender patients are diagnosed either at locally-advanced or advanced stages. It is important to note that trans male patients present a higher risk of breast cancer than the cis male patients. Nonetheless, it is not higher than the cis female population. Finally, I would like also to add that transgender patients have a lower likelihood to undergo any type of breast cancer screening during their lifetime, or to be up-to-date with their current screenings. We developed a 59 in survey applied to Mexican physicians that evaluated for current knowledge and attitudes towards breast cancer screening. Our questionnaire consisted of six items evaluating current attitudes, and nine items evaluating current knowledge on the topic. We applied this online survey during June 2022. Overall, we collected 165 consecutive answers. Most participants identified as cis male, followed as cis female people. They had an average age of 30.5 years, self-identified as heterosexual. Most were either residents or fellows, and they were part of a clinical specialty. When we related for current attitudes, we could see that most respondents did not feel comfortable with their current knowledge on the topic, as well as their current abilities to communicate effectively with their patients about breast cancer screening in the transgender population. Nonetheless, it is important to note that most participants consider it important that transgender health should be part of the current curricula, either during medical school, or during their residency or fellowship. When looking at their results regarding current knowledge, we could see that a large amount of participants correctly identified that being transgender could have a negative impact under current health, as it might imply having a later cancer diagnosis than in other populations. Specifically, looking at the results about the practical application of the breast cancer screening strategies, we can see that less than 50% of the participants were aware at the age of the current recommendations to start breast cancer screening strategies, and also the time interval for which they should be applying this type of imaging modalities. When looking at overall participants' performance, we can see that the average score of participants was very limited. Only 40.5 correct answers, which meant that only 3.7 questions were answered correctly. We concluded that the current physicians' knowledge about the topic is very limited. Nonetheless, most physicians consider it an important area of opportunity to be addressed through medical, through educational, and interventions in the future.

Related Videos

Symptom Management
Issues in Oncology

Dawn L. Hershman, MD, on Prophylactic Colony Stimulating Factors for Neutropenia: Improving Clinicians’ Prescribing Practices

Dawn L. Hershman, MD, of Columbia University College of Physicians and Surgeons, discusses findings that showed substantial variability in clinicians’ adherence to prescribing primary prophylactic colony stimulating factors in a pragmatic trial. Although the ability to opt out of the intervention is a feature of pragmatic trials, careful prestudy planning to estimate nonadherence is critical to ensure adequate power to detect an effect. Understanding reasons for intervention opt-outs may also inform future pragmatic studies aimed at improving adherence to practice guidelines.

Palliative Care

Xuesong Han, PhD, on Medicaid Expansion and Receipt of Palliative Care Among Individuals Newly Diagnosed With Advanced-Stage Cancers

Xuesong Han, PhD, of the American Cancer Society, discusses findings showing that among newly diagnosed patients with stage IV cancers, Medicaid expansion was associated with increases in receipt of palliative care, although overall usage was low. The increase varied by cancer type. Improving Medicaid coverage may facilitate access to guideline-based palliative care (Abstract 73).

Health-Care Policy

Justin M. Barnes, MD, on Medicaid Expansion and Changes in Cancer Mortality Rates

Justin M. Barnes, MD, of the Washington University School of Medicine, discusses the ways in which Medicaid expansion under the Affordable Care Act seems to affect distant diagnoses and cancer deaths per year, the differences in the impact of expansion between Black and White patients in the United States, and why insurance alone appears to be insufficient to overcome structural barriers to care for some populations.

Lung Cancer

Qinjin Fan, PhD, on Equitable Lung Cancer Care and Mortgage Discrimination

Qinjin Fan, PhD, of the American Cancer Society, explores the question of how mortgage discrimination is linked to lower rates of guideline-concordant care for patients with non–small cell lung cancer. This study highlights the critical need to understand the pathways through which mortgage denials may negatively affect the receipt of equitable care (Abstract 3).

Issues in Oncology

Joannie M. Ivory, MD, MSPH, on Increasing Participation of Black Patients With Cancer in Clinical Trials

Joannie M. Ivory, MD, MSPH, of The University of North Carolina at Chapel Hill, discusses ways to raise the number of Black patients with cancer who take part in clinical trials. More successful accrual may be linked to conducting trials where Black patients live and designing studies to recruit a concrete target percentage of marginalized populations.